Skip to main content
Top
Published in: Journal of Neuro-Oncology 2/2013

01-11-2013 | Clinical Study

Ongoing and prolonged response in adult low-grade gliomas treated with radiotherapy

Authors: F. Ducray, G. Kaloshi, C. Houillier, A. Idbaih, B. Ribba, D. Psimaras, Y. Marie, B. Boisselier, A. Alentorn, L. Dainese, S. Navarro, K. Mokhtari, M. Sanson, K. Hoang-Xuan, Jean-Yves Delattre

Published in: Journal of Neuro-Oncology | Issue 2/2013

Login to get access

Abstract

The aim of the present study was to evaluate the impact of first-line radiotherapy on low-grade gliomas (LGGs) growth kinetics. The mean tumor diameter (MTD) of 39 LGGs was retrospectively measured on serial magnetic resonance images before (n = 16) and after radiotherapy onset (n = 39). After radiotherapy, a decrease of the MTD was observed in 37 patients. Median duration of the MTD decrease was 1.9 years (range 0–8.1 years). According to RANO criteria, the rates of partial and minor responses were 15 and 28 % at the first evaluation after radiotherapy and 36 and 34 % at the time of maximal MTD decrease. The presence of a 1p19q codeletion and the absence of p53 expression were associated with longer durations of MTD decrease (5.3 vs 1 years, p = 0.02 and 2.4 vs 1.8 years, p = 0.05, respectively) while no association was observed between IDH1-R132H expression and duration of MTD decrease. In most patients, MTD decrease after radiotherapy occurred in two phases: an initial phase of rapid MTD decrease followed by a second phase of slower MTD decrease. Patients with a high rate of MTD decrease during the initial phase (>7 mm/year) had both a shorter duration of response (1.9 vs 5.3 years, p = 0.003) and a shorter overall survival (5.5 vs 11.6 years, p = 0.0004). LGGs commonly display a prolonged and ongoing volume decrease after radiotherapy. However, patients who respond rapidly should be carefully monitored because they are at a higher risk of rapid progression.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mandonnet E, Delattre JY, Tanguy ML et al (2003) Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol 53:524–528PubMedCrossRef Mandonnet E, Delattre JY, Tanguy ML et al (2003) Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol 53:524–528PubMedCrossRef
2.
3.
go back to reference Peyre M, Cartalat-Carel S, Meyronet D et al (2010) Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol 12:1078–1082PubMedCentralPubMedCrossRef Peyre M, Cartalat-Carel S, Meyronet D et al (2010) Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol 12:1078–1082PubMedCentralPubMedCrossRef
4.
go back to reference Ricard D, Kaloshi G, Amiel-Benouaich A et al (2007) Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol 61:484–490PubMedCrossRef Ricard D, Kaloshi G, Amiel-Benouaich A et al (2007) Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol 61:484–490PubMedCrossRef
5.
go back to reference Soffietti R, Baumert BG, Bello L et al (2010) Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol 17:1124–1133PubMedCrossRef Soffietti R, Baumert BG, Bello L et al (2010) Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol 17:1124–1133PubMedCrossRef
6.
go back to reference van den Bent MJ, Wefel JS, Schiff D et al (2011) Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 12:583–593PubMedCrossRef van den Bent MJ, Wefel JS, Schiff D et al (2011) Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 12:583–593PubMedCrossRef
7.
go back to reference Desestret V, Ciccarino P, Ducray F et al (2011) Prognostic stratification of gliomatosis cerebri by IDH1 R132H and INA expression. J Neurooncol 105:219–224PubMedCrossRef Desestret V, Ciccarino P, Ducray F et al (2011) Prognostic stratification of gliomatosis cerebri by IDH1 R132H and INA expression. J Neurooncol 105:219–224PubMedCrossRef
8.
go back to reference Kaloshi G, Benouaich-Amiel A, Diakite F et al (2007) Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 68:1831–1836PubMedCrossRef Kaloshi G, Benouaich-Amiel A, Diakite F et al (2007) Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 68:1831–1836PubMedCrossRef
9.
go back to reference Bauman G, Pahapill P, Macdonald D et al (1999) Low grade glioma: a measuring radiographic response to radiotherapy. Can J Neurol Sci 26:18–22PubMed Bauman G, Pahapill P, Macdonald D et al (1999) Low grade glioma: a measuring radiographic response to radiotherapy. Can J Neurol Sci 26:18–22PubMed
10.
go back to reference Eyre HJ, Crowley JJ, Townsend JJ et al (1993) A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J Neurosurg 78:909–914PubMedCrossRef Eyre HJ, Crowley JJ, Townsend JJ et al (1993) A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J Neurosurg 78:909–914PubMedCrossRef
11.
go back to reference Lunsford LD, Somaza S, Kondziolka D et al (1995) Survival after stereotactic biopsy and irradiation of cerebral nonanaplastic, nonpilocytic astrocytoma. J Neurosurg 82:523–529PubMedCrossRef Lunsford LD, Somaza S, Kondziolka D et al (1995) Survival after stereotactic biopsy and irradiation of cerebral nonanaplastic, nonpilocytic astrocytoma. J Neurosurg 82:523–529PubMedCrossRef
12.
go back to reference Pallud J, Llitjos JF, Dhermain F et al (2012) Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas. Neuro Oncol 14:496–505PubMedCentralPubMedCrossRef Pallud J, Llitjos JF, Dhermain F et al (2012) Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas. Neuro Oncol 14:496–505PubMedCentralPubMedCrossRef
13.
go back to reference Ribba B, Kaloshi G, Peyre M et al (2012) A tumor growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapy. Clin Cancer Res 18:5071–5080PubMedCrossRef Ribba B, Kaloshi G, Peyre M et al (2012) A tumor growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapy. Clin Cancer Res 18:5071–5080PubMedCrossRef
14.
go back to reference Cairncross G, Berkey B, Shaw E et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714PubMedCrossRef Cairncross G, Berkey B, Shaw E et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714PubMedCrossRef
15.
go back to reference van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715–2722PubMedCrossRef van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715–2722PubMedCrossRef
Metadata
Title
Ongoing and prolonged response in adult low-grade gliomas treated with radiotherapy
Authors
F. Ducray
G. Kaloshi
C. Houillier
A. Idbaih
B. Ribba
D. Psimaras
Y. Marie
B. Boisselier
A. Alentorn
L. Dainese
S. Navarro
K. Mokhtari
M. Sanson
K. Hoang-Xuan
Jean-Yves Delattre
Publication date
01-11-2013
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 2/2013
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-013-1224-1

Other articles of this Issue 2/2013

Journal of Neuro-Oncology 2/2013 Go to the issue